Incyte (INCY) revenue: $5.1B
Incyte reported $5.1B of revenue for the year ended Dec 31, 2025, up 21.2% from $4.2B a year earlier.
From Incyte's filings with the SEC · Read the filing · INCY stock page
Incyte revenue by year
#684 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $5.1B | +21% |
| Dec 31, 2024 | $4.2B | +15% |
| Dec 31, 2023 | $3.7B | +9% |
| Dec 31, 2022 | $3.4B | +14% |
| Dec 31, 2021 | $3B | – |
Revenue of similar companies
Companies in the same industry as Incyte, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Iqvia | $16.3B | Dec 31, 2025 |
| Icon | $8.3B | Dec 31, 2025 |
| Incyte | $5.1B | Dec 31, 2025 |
| Charles River Laboratories International | $4B | Dec 27, 2025 |
| Medpace Holdings | $2.5B | Dec 31, 2025 |
| OmniAb | $18.7M | Dec 31, 2025 |
| Absci | $2.8M | Dec 31, 2025 |
Questions and answers
What is Incyte's revenue?
Incyte reported $5.1B of revenue for the year ended Dec 31, 2025, up 21.2% from $4.2B a year earlier.
Numbers as reported in Incyte's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology